Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Cortés, Javier; S. Rugo, Hope; W. Cescon, David; Im, Seock‐Ah; Md Yusof, Mastura; Gallardo, Carlos; Lipatov, Oleg; H. Barrios, Carlos; Manuel Pérez-García, José; Iwata, Hiroji; Masuda, Norikazu; Torregroza Otero, Marco; Gokmen, Erhan; Loi, Sherene; Guo, Zifang; Zhou, Xuan; Karantza, Vassiliki; Pan, Wilbur; Schmid, Peter

doi:10.1056/nejmoa2202809

Public

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Published in New England Journal of Medicine • Jul 20, 2022

Authors:

Javier Cortés

Hope S. Rugo

David W. Cescon

Abstract

BACKGROUND: In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a comb...

Subject

Pembrolizumab

Triple-negative breast cancer

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!